lobbying_activities: 2268767

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2268767	eafa69fe-982d-4259-80db-fe012ea096e6	Q1	DAVIS & HARMAN LLP	11674	EMERGENT BIOSOLUTIONS, INC.	2019	first_quarter	DIS	FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Reauthorization of the Pandemic and All-Hazards Preparedness Act. NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical countermeasures. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin legislation. Naloxone access, coprescribing/opioid prescribing guidelines.	HOUSE OF REPRESENTATIVES,SENATE	10000		0	0	2019-04-17T11:40:46.387000-04:00